Analyst Research

Report Title Price
Provider: Reuters Investment Profile
Provider: GlobalData
Provider: GlobalData
Provider: GlobalData

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sartorius Stedim Biotech SA Raises FY 2012 Guidance in Line with Analysts Estimates

Monday, 29 Oct 2012 01:44am EDT 

Sartorius Stedim Biotech SA announced that it has raised its guidance for fiscal year 2012. Sales revenue is expected to grow by about 11% in constant currencies (former guidance: about 10%); the Group's underlying earnings are projected to rise by about 20% (former guidance: about 15%), provided that currency exchange rates remain favorable as in the first nine months of this year. In 2011 the Company reported revenue of EUR 477.30 million. According to I/B/E/S Estimates, analysts on average are expecting the Company to report fiscal year 2012 revenue of EUR 539.25 million. 

Company Quote

-3.55 -2.71%
10 Jul 2014